Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Stephens cut its rating on Cheesecake Factory to Equal Weight from Overweight while retaining a $65 price target, pointing to limited upside at current levels given elevated valuation after a roughly 27% year-to-date rally. The restaurant operator delivered fiscal Q4 2025 results that beat consensus on revenue and adjusted EPS, but same-store sales…
Morgan Stanley tells investors that a post-earnings decline in one auto retailer's stock presents an attractive entry point. The bank acknowledges a weaker fourth-quarter print and higher per-unit reconditioning costs but maintains conviction in the company's long-term growth path, citing its integrated financing platform, improving leverage metric…
Hims & Hers Health, Inc. saw its shares rise 7.8% Thursday morning after announcing a definitive agreement to acquire Eucalyptus, an international digital health group operating in Australia, the UK, Germany, Japan, and Canada. The transaction, valued at up to $1.15 billion USD, includes an initial cash payment of roughly $240 million and deferred …
HSBC upgraded QuantumScape (NASDAQ: QS) from Reduce to Hold and set a new price target of $8.30, down from $10.50. The move follows the company meeting several 2025 operational milestones, including the integration of Cobra into cell production and shipments of Cobra-integrated QSE-5 cells, even as investors have punished the stock amid broader con…
Charter Hall Group shares fell after an initial strong market reaction to its first-half 2026 results as the company guided to higher operating costs for fiscal 2026. Management said the uplift in expenses reflects bonus accruals tied to operational performance rather than an erosion of fixed-cost leverage. Much of the capital deployment and inflow…
A multi-year supply agreement between Nvidia and Meta provided modest support for Big Tech, yet gains were capped as oil surged, credit strains emerged and Federal Reserve minutes signaled reluctance to ease policy. Markets face geopolitical risks from U.S.-Iran and Ukraine-Russia tensions, while rare earth prices have climbed above a U.S. price fl…
Delta offers a compelling risk-reward setup: steady free cash flow ($3.84B), falling leverage (debt/equity ~0.73), and undervalued multiples (P/E ~9.3, EV/EBITDA ~4.0). This trade targets a re-rating to ~12-13x EPS over the next 180 trading days, with a clear stop to protect against cyclical shocks.
UBS downgraded Freenet from Neutral to Sell and left its price target at €28.50. The broker cited stretched valuation after recent share gains, weakening trends in the mobile and Waipu TV businesses, and a longer-term risk from AI-driven changes to customer acquisition and retention. Freenet stock fell roughly 10% in Germany on the news.
Wells Fargo launched coverage of AxoGen, Inc. (NASDAQ: AXGN) with an overweight rating and a $40.00 price target, implying roughly 13% upside from the current share price of $35.25. The bank highlighted AxoGen's exclusive focus on peripheral nerve repair and its lead off-the-shelf biologic graft product, Avance, as core advantages. The company is e…
Morgan Stanley raised Capgemini SA’s rating to equal-weight from underweight, pointing to a pronounced share price decline that has improved the stock’s risk-reward profile. The bank trimmed its price target to €117 from €142 due to a higher WACC and concerns about medium-term growth visibility amid potential AI-driven disruption. Capgemini posted …
TD Cowen has started coverage of GRAIL, Inc. (NASDAQ: GRAL) with a Hold rating and a $114 price target, reflecting an 11% potential upside from the stock's then-current price of $102.28. The firm's diligence — including calls with key opinion leaders, surveys, and literature reviews — supports a positive view of the multi-cancer early detection mar…
Hims & Hers Health announced it will acquire Australian digital health company Eucalyptus in a transaction valued at up to $1.15 billion. The purchase is designed to extend Hims & Hers' personalized care offerings into Australia and Japan and to strengthen access in the United Kingdom, Germany and Canada through regional partnerships. The deal incl…
Figma's stock jumped roughly 14% in premarket trading after the design-software firm provided a stronger-than-expected revenue forecast for 2026 and detailed plans to monetize embedded AI capabilities. Management said it will introduce AI credits and enforce limits for high-usage customers, while cautioning that AI investments, expanded operations …
UBS raised its recommendation on XL Axiata to Neutral from Sell while trimming its price target to IDR3,300 from IDR3,600. The bank cites stretched valuation metrics and the need for clearer merger synergy evidence before earnings momentum emerges, even as pricing trends and ARPU gains show improvement.
Canaccord Genuity has initiated coverage of Kiniksa Pharmaceuticals Inc. (KNSA) with a Buy rating and a $62 price target, noting the company’s commercial positioning around Arcalyst (rilonacept) for recurrent pericarditis. The stock is trading near its 52-week high after a strong one-year gain, while company revenues and physician adoption metrics …
Piper Sandler launched coverage of Perspective Therapeutics Inc (NYSE:CATX) with an overweight rating and a $16 price target, implying more than 200% upside from the stock's $5.03 level. The firm pointed to the company’s lead 212-based radiotherapy candidate, VMT-α-NET, and a distinctive safety profile as key positives. The company recently priced …
Deere & Co raised its full-year 2026 net income forecast after earlier cost reductions helped blunt the effect of weak equipment demand. The lift in guidance and signs of recovering demand in particular segments supported a premarket share increase. Management continues to work with dealers on inventory and had earlier cut factory production to mat…
Teck Resources reported adjusted fourth-quarter earnings above analyst expectations, driven by higher realized copper prices and increased production. The Canadian miner reiterated its 2026 copper output guidance while moving forward with a proposed all-stock merger with Anglo American that shareholders previously approved. Final regulatory clearan…
Barclays downgraded BASF to "underweight" and set a €40 price target, which implies about 21% downside from the Feb. 17 closing price of €50.62. The bank reduced its 2026 adjusted EBITDA forecast and highlighted a range of operational and structural risks including weak fourth-quarter results, potential European emissions cost increases, and challe…
Mizuho has begun coverage of Tempus AI Inc (NASDAQ: TEM) with an Outperform rating and a $100 price target, implying roughly 78% upside from recent levels. The broker highlights Tempus AI's strength in tissue-informed genomic profiling and potential growth in liquid biopsies, while third-party fair value analysis flags possible overvaluation at cur…
The Bundesbank says Germany's recovery will continue but with muted growth in the first quarter, and expects a stronger expansion from spring driven chiefly by fiscal stimulus. Headwinds for Q1 include weather-damaged construction activity and a likely cooling of private consumption, while industry faces export competitiveness challenges despite so…
President Donald Trump will speak in Rome, Georgia, focusing on measures he says will reduce costs for working Americans. The address comes as inflation readings show modest overall easing but persistent price pressures in food and housing, and as Republican control of Congress faces election-year uncertainty.
New drilling equipment arriving in Venezuela has raised hopes of a near-term uptick in crude production, but operators and service providers say even the simplest projects are complicated by damaged infrastructure, lost data, shortages of diluents and security and legal uncertainties. Early fixes using existing rigs, refurbishing wells and repairin…
A federal legal clash over California's longstanding authority to set its own vehicle-emissions rules has placed U.S. automakers in a precarious position. If congressional Republicans and the Trump administration prevail in revoking California's waiver, automakers could avoid stricter state mandates that favor electric vehicles (EVs). If California…
Hims & Hers’ announcement of a $49 compounded oral semaglutide pill intended to expand its weight-loss franchise provoked a swift response from regulators and Novo Nordisk, which called the product an illegal imitation and filed a patent suit. The retreat highlights manufacturing and regulatory hurdles for compounded GLP-1 products and raises quest…
